OncoMatch/Clinical Trials/NCT04256018
Mogamulizumab + Low-Dose Total Skin Electron Beam Tx in Mycosis Fungoides & Sézary Syndrome
Is NCT04256018 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Mogamulizumab for sezary syndrome.
Treatment: Mogamulizumab — The purpose of this study is to determine the efficacy of the combination of LD-TSEBT and mogamulizumab in patients with MF and SS. And to evaluate the secondary measures of clinical benefit of the combination therapy and to evaluate the safety and tolerability of the combination in patients with MF and SS.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Hodgkin Lymphoma
Disease stage
Required: Stage IB, IIA, IIB, III, IV
Excluded: Stage IA
Stages IB-IV MF or SS; MF with limited disease (Stage IA) or central nervous system (CNS) disease [excluded]
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Lab requirements
Blood counts
ANC ≥ 1,000/μL; Platelets ≥ 75,000/μL
Kidney function
Calculated creatinine clearance ≥ 30 mL/min using Cockcroft-Gault formula
Liver function
Bilirubin ≤ 1.5 x ULN (≤ 5 x ULN if Gilbert's syndrome); AST/ALT ≤ 2.5 x ULN (≤ 5 x ULN with hepatic involvement by CTCL)
Adequate hematologic function: ANC ≥ 1,000 cells/μL; Platelets ≥ 75,000 cells/μL. Adequate hepatic function: Bilirubin ≤ 1.5 x ULN (≤ 5 x ULN if Gilbert's syndrome); AST/ALT ≤ 2.5 x ULN (≤ 5 x ULN with hepatic involvement by CTCL). Adequate renal function: Calculated creatinine clearance ≥ 30 mL/min using Cockcroft-Gault formula.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Stanford Cancer Center · Stanford, California
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify